Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Marshfield Clinic - Indianhead Center
mi
from
Rice Lake, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Marshfield Clinic - Indianhead Center
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Saint Michael's Hospital Cancer Center
mi
from
Stevens Point, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Saint Michael's Hospital Cancer Center
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Tom Baker Cancer Centre - Calgary
mi
from
Calgary,
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Tom Baker Cancer Centre - Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients
A Pilot Study of Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients Using On-Board Imaging System With Linear Accelerator
Status: Enrolling
Updated:  10/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients
A Pilot Study of Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients Using On-Board Imaging System With Linear Accelerator
Status: Enrolling
Updated: 10/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
UCSD Medical Center- La Jolla
mi
from
La Jolla, CA
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
UCSD Medical Center- La Jolla
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
UCSD Medical Center - Hillcrest
mi
from
San Diego, CA
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
UCSD Medical Center - Hillcrest
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Washington Cancer Institute (WCI) at Washington Hospital Center (WHC)
mi
from
Washington,
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Washington Cancer Institute (WCI) at Washington Hospital Center (WHC)
mi
from
Washington,
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Florida Cancer Research Institute
mi
from
Davie, FL
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Florida Cancer Research Institute
mi
from
Davie, FL
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Florida Cancer Research Institute
mi
from
Plantation, FL
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Florida Cancer Research Institute
mi
from
Plantation, FL
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Central Baptist Hospital
mi
from
Lexington, KY
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Central Baptist Hospital
mi
from
Lexington, KY
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Lexington Oncology Associates
mi
from
Lexington, KY
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Lexington Oncology Associates
mi
from
Lexington, KY
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Bluegrass Hematology/Oncology, PSC
mi
from
Lexington, KY
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Bluegrass Hematology/Oncology, PSC
mi
from
Lexington, KY
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Massachusetts General Hospital
mi
from
Boston, MA
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Bringham and Women's Hospital
mi
from
Boston, MA
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Bringham and Women's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Dana Farber Cancer Institute (DFCI)
mi
from
Boston, MA
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Dana Farber Cancer Institute (DFCI)
mi
from
Boston, MA
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
University of Minnesota Medical Center-Fairview, Riverside Campus
mi
from
Minneapolis, MN
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
University of Minnesota Medical Center-Fairview, Riverside Campus
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Alamance Regional Medical Center Cancer Center
mi
from
Burlington, NC
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Alamance Regional Medical Center Cancer Center
mi
from
Burlington, NC
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Duke University Medical Center - Morris Cancer Center Clinics
mi
from
Durham, NC
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Duke University Medical Center - Morris Cancer Center Clinics
mi
from
Durham, NC
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Duke University Medical Center, Department of Medicine - Oncology
mi
from
Durham, NC
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Duke University Medical Center, Department of Medicine - Oncology
mi
from
Durham, NC
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Duke University Medical Center-Duke Cancer Center
mi
from
Durham, NC
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Duke University Medical Center-Duke Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Duke University School of Medicine
mi
from
Durham, NC
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Duke University School of Medicine
mi
from
Durham, NC
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Texas Oncology - PA Collins Building 5th Floor
mi
from
Dallas, TX
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Texas Oncology - PA Collins Building 5th Floor
mi
from
Dallas, TX
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Baylor College Of Medicine (Bcm)
mi
from
Houston, TX
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Baylor College Of Medicine (Bcm)
mi
from
Houston, TX
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Baylor College of Medicine Breast Center
mi
from
Houston, TX
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Baylor College of Medicine Breast Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Fletcher Allen Healthcare
mi
from
Burlington, VT
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Fletcher Allen Healthcare
mi
from
Burlington, VT
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Fletcher Allen Health Care
mi
from
Burlington, VT
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Fletcher Allen Hospital MCHV Campus
mi
from
Burlington, VT
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Fletcher Allen Hospital MCHV Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Pharmacist, Investigational Drug Service
mi
from
Burlington, VT
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Pharmacist, Investigational Drug Service
mi
from
Burlington, VT
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Fletcher Allan Health Care
mi
from
Burlington, VT
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Fletcher Allan Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Policlinica Privada Site La Plata S.A.
mi
from
La Plata,
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Policlinica Privada Site La Plata S.A.
mi
from
La Plata,
Click here to add this to my saved trials
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
A Phase II Clinical Trial of Intermittent Letrozole Therapy in Postmenopausal Women With CA 15-3 Positive, Hormone Receptor Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
A Phase II Clinical Trial of Intermittent Letrozole Therapy in Postmenopausal Women With CA 15-3 Positive, Hormone Receptor Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
A Phase II Clinical Trial of Intermittent Letrozole Therapy in Postmenopausal Women With CA 15-3 Positive, Hormone Receptor Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Massachusetts General Hospital
mi
from
Boston, MA
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
A Phase II Clinical Trial of Intermittent Letrozole Therapy in Postmenopausal Women With CA 15-3 Positive, Hormone Receptor Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings
Status: Enrolling
Updated:  10/6/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings
Status: Enrolling
Updated: 10/6/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated:  10/6/2015
Emory University Hospital - Atlanta
mi
from
Atlanta, GA
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated: 10/6/2015
Emory University Hospital - Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated:  10/6/2015
Veterans Affairs Medical Center - Atlanta (Decatur)
mi
from
Decatur, GA
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated: 10/6/2015
Veterans Affairs Medical Center - Atlanta (Decatur)
mi
from
Decatur, GA
Click here to add this to my saved trials
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated:  10/6/2015
CCOP - Evanston
mi
from
Evanston, IL
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated: 10/6/2015
CCOP - Evanston
mi
from
Evanston, IL
Click here to add this to my saved trials
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated:  10/6/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated: 10/6/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated:  10/6/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated: 10/6/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated:  10/6/2015
Veterans Affairs Medical Center - Indianapolis (Roudebush)
mi
from
Indianapolis, IN
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast
Status: Enrolling
Updated: 10/6/2015
Veterans Affairs Medical Center - Indianapolis (Roudebush)
mi
from
Indianapolis, IN
Click here to add this to my saved trials